Last updated: July 31, 2026
Chlorpheniramine maleate plus pseudoephedrine hydrochloride is a mature, low-cost oral combination used for temporary relief of nasal congestion, runny nose, sneezing and related upper-respiratory symptoms. The product has limited current clinical-development activity because both ingredients are long-established OTC drugs. Market growth is likely to remain modest and volume-driven, with demand concentrated in generic, private-label and regional pharmacy products.
The principal commercial risks are pseudoephedrine sales restrictions, pharmacist-counter requirements, competition from newer antihistamine/decongestant combinations, consumer preference for non-sedating products and substitution with single-ingredient therapies.
What is the current FDA status of chlorpheniramine and pseudoephedrine?
In the United States, chlorpheniramine maleate and pseudoephedrine hydrochloride are established OTC active ingredients. Their regulatory framework is primarily based on the FDA OTC monograph system rather than a modern, single-product new drug application.
Chlorpheniramine is a first-generation antihistamine. It can reduce sneezing, rhinorrhea and nasal symptoms but may cause drowsiness, impaired alertness, dry mouth and anticholinergic effects.
Pseudoephedrine is a sympathomimetic nasal decongestant. It can relieve nasal congestion but may cause insomnia, nervousness, increased blood pressure, palpitations and urinary-retention symptoms in susceptible patients.
The relevant FDA framework includes the OTC Monograph M012 for internal analgesic, antipyretic and antirheumatic products and the antihistamine and decongestant provisions in 21 C.F.R. Part 341. Product-specific labeling, dosage form and combination restrictions remain important because an individual combination must comply with the applicable monograph conditions or obtain FDA approval through another regulatory route (U.S. Food and Drug Administration, 2024a; Electronic Code of Federal Regulations, 2025).
| Regulatory item |
Current position |
| Active ingredients |
Chlorpheniramine maleate and pseudoephedrine hydrochloride |
| Primary U.S. pathway |
OTC monograph or approved legacy product, depending on product history |
| Prescription requirement |
Usually OTC, but pseudoephedrine products are subject to controlled-sale requirements |
| New chemical entity exclusivity |
None |
| Biologic exclusivity |
Not applicable |
| Orange Book status |
Combination products marketed under the OTC monograph framework generally are not listed as NDA products |
| Main regulatory issue |
Compliance with OTC monograph conditions and pseudoephedrine sales controls |
Are there active clinical trials for chlorpheniramine maleate plus pseudoephedrine hydrochloride?
There is no material late-stage clinical-development program for this combination comparable to a new prescription drug. The clinical evidence base is largely historical and supports short-term symptomatic use rather than disease modification.
ClinicalTrials.gov contains studies involving antihistamines, decongestants and upper-respiratory symptoms, but the combination is not a current biotechnology or specialty-pharmaceutical development asset. Newer trials tend to evaluate respiratory infections, allergic rhinitis, intranasal therapies, non-sedating antihistamines or novel decongestant approaches rather than re-establishing the clinical value of this legacy oral combination (National Library of Medicine, 2025).
What clinical endpoints are relevant?
Historical and postmarketing evaluations generally focus on:
- Nasal airflow and congestion scores
- Sneezing and rhinorrhea
- Symptom-relief onset and duration
- Sedation and psychomotor impairment
- Blood pressure and heart-rate effects
- Adverse events in children, older adults and patients with cardiovascular disease
The commercial evidence burden is therefore different from that of a new drug. Manufacturers primarily need to demonstrate compliance with permitted active ingredients, dosage strengths, labeling and manufacturing standards. They do not generally need to fund a new pivotal efficacy program for each generic or private-label version.
What formulations are protected by chlorpheniramine-pseudoephedrine products?
The main formulation opportunities are dosage convenience and release profile rather than novel pharmacology.
| Formulation type |
Commercial role |
Development value |
| Immediate-release tablet |
Low-cost relief with multiple daily dosing |
Low |
| Extended-release tablet |
Longer duration and reduced dosing frequency |
Moderate, but difficult to defend with patents |
| Liquid or oral solution |
Pediatric or swallowing-difficulty use |
Limited, with safety and dosing constraints |
| Combination cold product |
Symptom bundling and retail positioning |
Low to moderate |
| Single-dose or sustained-release system |
Convenience and adherence |
Limited unless supported by meaningful clinical differentiation |
Extended-release products may require more complex dissolution testing, stability work and manufacturing controls. Those requirements can create operational barriers, but they do not necessarily create durable market exclusivity. A competitor can challenge a formulation through an alternative release mechanism, dosage strength or delivery design.
The principal technical risks include instability in liquid products, dose-uniformity problems, alcohol or sugar content, misuse by children, and interactions with other OTC cold products containing overlapping ingredients.
What patents protect chlorpheniramine maleate and pseudoephedrine hydrochloride?
The active ingredients are old, off-patent compounds. Any original compound patents associated with chlorpheniramine or pseudoephedrine expired many decades ago. The combination does not have modern small-molecule exclusivity.
Potential intellectual-property categories include:
- Extended-release matrices and coatings.
- Specific ratios of antihistamine to decongestant.
- Liquid formulations and taste-masking systems.
- Manufacturing processes and impurity controls.
- Packaging intended to reduce misuse or improve stability.
- Method-of-use claims for defined patient groups or symptom profiles.
These rights are generally narrower than an active-ingredient patent and may be vulnerable to invalidity, design-around or non-infringement arguments. The commercial value of a formulation patent depends on whether the claim covers a widely used product architecture and whether the product generates sufficient margin to support enforcement.
How many patents cover the combination?
There is no single, commercially controlling patent estate comparable to the estates surrounding newer branded medicines. Standard immediate-release chlorpheniramine-pseudoephedrine products are generally available through generic and private-label channels without a meaningful composition-of-matter barrier.
A patent search should distinguish between:
- Expired historical patents.
- Abandoned applications.
- Narrow formulation claims.
- Continuations with no marketed product.
- Foreign rights that do not affect U.S. entry.
- Patents covering a brand or package rather than the active formulation.
When does chlorpheniramine-pseudoephedrine lose exclusivity?
The combination has already lost core exclusivity in the United States and other major markets. The relevant commercial question is not the date of first generic entry. It is whether a specific extended-release, liquid or branded formulation has enforceable secondary rights.
| Exclusivity category |
Position |
| Compound patent |
Expired |
| Combination patent |
No generally controlling modern estate |
| NCE exclusivity |
Expired or not applicable |
| Pediatric exclusivity |
Not a current commercial barrier |
| Orphan exclusivity |
Not applicable |
| OTC monograph protection |
Regulatory standard, not market exclusivity |
| Formulation exclusivity |
Product-specific and potentially narrow |
What is the Orange Book status of the combination?
The Orange Book is principally an index of approved prescription and certain other FDA-approved drug products, their patents and therapeutic equivalence ratings. OTC monograph products are generally not listed in the same manner as approved NDA products.
As a result, a standard OTC chlorpheniramine-pseudoephedrine product usually does not present the same Orange Book patent-certification profile as a branded prescription drug. If a particular combination is marketed under an approved NDA, its status must be assessed separately by product number and application history. The active ingredients alone do not establish Orange Book protection (U.S. Food and Drug Administration, 2025a).
Which companies are challenging the product through Paragraph IV filings?
Paragraph IV litigation is not the normal entry mechanism for a product marketed solely under the OTC monograph system. A generic applicant using the abbreviated new drug application pathway may encounter Orange Book patents only if the reference product is an approved NDA product with listed patents.
For standard OTC versions, competition generally occurs through:
- Monograph-compliant private-label launches.
- Abbreviated applications where applicable.
- Retailer sourcing changes.
- Contract manufacturing.
- Reformulation and packaging changes.
- Substitution with other antihistamine-decongestant combinations.
No major, current U.S. Paragraph IV dispute is broadly associated with the standard chlorpheniramine maleate-pseudoephedrine hydrochloride combination.
What litigation and settlement risks affect the market?
The market has limited litigation value because the active ingredients are old and low priced. Litigation risk is more likely to involve:
- Product liability claims related to sedation or cardiovascular events.
- Labeling and advertising disputes.
- FDA compliance actions.
- Trademark and trade-dress issues.
- Patent disputes involving extended-release technology.
- State restrictions involving pseudoephedrine sales and diversion.
Settlement agreements, if any, are more likely to concern commercial distribution, branding or manufacturing than a patent-protected launch date. A formulation dispute would have to be evaluated at the claim level because a competitor can often market an alternative immediate-release or modified-release design.
How does the market compare with competing allergy and cold medicines?
Chlorpheniramine-pseudoephedrine competes in several overlapping segments.
| Product category |
Competitive position |
| Loratadine-pseudoephedrine |
Stronger non-sedating positioning; often preferred for daytime allergy use |
| Cetirizine-pseudoephedrine |
Competes on newer-generation antihistamine positioning |
| Fexofenadine-pseudoephedrine |
Strong non-sedating profile, typically higher price |
| Diphenhydramine-pseudoephedrine |
Similar first-generation antihistamine competition, with sedation concerns |
| Phenylephrine products |
Broad retail availability, although oral efficacy has faced FDA scrutiny |
| Pseudoephedrine alone |
Often preferred when antihistamine effects are not needed |
| Intranasal corticosteroids |
Stronger long-term allergic-rhinitis positioning |
| Saline and non-drug products |
Increasingly relevant for consumers avoiding systemic adverse effects |
The combination retains a cost advantage and can be effective for consumers who need both antihistamine and decongestant activity. Its main weakness is the sedation profile of chlorpheniramine and the regulatory friction surrounding pseudoephedrine.
What is the market size and revenue outlook?
A reliable global revenue figure for this exact combination is difficult to isolate because sales are reported within broader OTC cold, allergy and respiratory categories. The product is frequently sold as a generic or retailer-branded SKU, and manufacturers do not consistently disclose combination-specific revenue.
The likely market profile is:
- Mature demand with limited unit growth.
- Low average selling prices.
- High private-label exposure.
- Seasonal volume peaks during allergy and cold seasons.
- Margin pressure from retailer negotiations.
- Strong substitution across active ingredients.
- Greater growth potential in emerging markets than in the United States.
2025-2030 projection
| Scenario |
Unit outlook |
Revenue outlook |
Main drivers |
| Base case |
Flat to low-single-digit growth |
Flat to low-single-digit growth |
Stable demand, price competition |
| Upside case |
Low-single-digit growth |
Low- to mid-single-digit growth |
Seasonal respiratory demand and private-label expansion |
| Downside case |
Low-single-digit decline |
Flat to decline |
Pseudoephedrine restrictions, substitution and safety concerns |
The strongest commercial opportunities are likely to come from supply reliability, low-cost manufacturing, compliant packaging and retailer distribution rather than from clinical differentiation.
What generic launch scenarios exist?
Immediate-release generic launch
This is the lowest-risk pathway. Competition can enter through existing monograph conditions or established approved-product pathways, depending on the product. Pricing is likely to be aggressive, and differentiation is limited.
Extended-release launch
This pathway offers improved dosing convenience but requires more complex formulation and bioavailability work. A competitor may gain a temporary commercial advantage through product design, but durable exclusivity depends on enforceable formulation claims.
Private-label launch
Retailers can use contract manufacturers to market the combination under store brands. This model can rapidly increase price pressure on branded products.
Reformulated launch
A manufacturer may shift toward a non-sedating antihistamine, pseudoephedrine-only product or intranasal therapy. Such products compete for the same consumer need without relying on the exact combination.
What manufacturing and IP barriers exist?
Manufacturing barriers are moderate but not high. The active ingredients are established, widely sourced and suitable for conventional solid oral dosage forms. The main operational requirements include:
- Control of assay and impurity profiles.
- Uniformity of low-dose chlorpheniramine.
- Pseudoephedrine supply-chain controls.
- Tamper-resistant or compliant packaging.
- Stability testing for liquids and extended-release products.
- Accurate pediatric dosing instructions.
- Segregated handling and recordkeeping where required by pseudoephedrine regulations.
Pseudoephedrine controls can increase distribution costs and complicate inventory management. These controls are regulatory and operational barriers rather than patent barriers.
Key Takeaways
- Chlorpheniramine maleate plus pseudoephedrine hydrochloride is a mature OTC combination with no meaningful new-drug clinical pipeline.
- Core active-ingredient and combination exclusivity has expired.
- Standard OTC products generally do not rely on Orange Book-listed patents.
- Formulation patents may exist for extended-release, liquid or specialized products, but they are likely to be narrow.
- Paragraph IV litigation is not the primary competitive mechanism for monograph-based products.
- The U.S. market should remain stable to modestly declining in units, with low-single-digit revenue growth at most.
- Private-label manufacturing, supply reliability and regulatory compliance matter more than clinical innovation.
- Loratadine-pseudoephedrine, cetirizine-pseudoephedrine, fexofenadine-pseudoephedrine and intranasal therapies create substantial substitution risk.
FAQs
Is chlorpheniramine-pseudoephedrine still sold in the United States?
Yes. Products containing the two ingredients remain available through generic, private-label and regional OTC channels, subject to FDA labeling requirements and pseudoephedrine sales controls.
Does chlorpheniramine-pseudoephedrine require a prescription?
The combination is generally marketed OTC, but pseudoephedrine products may be sold from behind the pharmacy counter and require purchase records or identification under federal and state rules.
Is chlorpheniramine-pseudoephedrine more effective than loratadine-pseudoephedrine?
The products have different pharmacologic profiles. Chlorpheniramine may provide effective antihistamine relief but is more sedating. Loratadine is generally positioned as a less-sedating alternative.
Can a company obtain new patents on this old combination?
A company cannot obtain a new composition-of-matter patent on the old active ingredients merely by combining them. It may seek narrower patents covering a novel release system, formulation, manufacturing process or specific use, subject to patentability requirements.
What is the principal investment risk for this product category?
The principal risks are low margins, retailer and private-label competition, pseudoephedrine restrictions, consumer migration to non-sedating or intranasal products, and limited ability to create defensible differentiation.
References
Electronic Code of Federal Regulations. (2025). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
National Library of Medicine. (2025). ClinicalTrials.gov. https://clinicaltrials.gov/
U.S. Food and Drug Administration. (2024a). Over-the-counter monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
U.S. Food and Drug Administration. (2025a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2025b). Regulation of pseudoephedrine products. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pseudoephedrine-and-ephedrine-products and https://www.fda.gov/drugs/information-drug-class/pseudoephedrine-and-ephedrine-products
